Chemical pathology of homocysteine. V. thioretinamide, thioretinaco, and cystathionine synthase function in degenerative diseases

Annals of Clinical and Laboratory Science

Volumn 41, Issue 4, 2011, Pages 301-314

  McCully, Kilmer S ^a  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Ascorbate; Cystathionine synthase; Homocysteine; Hydrogen sulfide; Nitrilosides; Pancreatic enzymes; Thioretinaco; Thioretinamide

Indexed keywords

ASCORBIC ACID; CHORIONIC GONADOTROPIN; CYSTATHIONINE SYNTHETASE; HEME OXYGENASE; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONE; HYDROGEN SULFIDE; NITRILE; NITRILOSIDE; OZONE; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RETINOL; SOMATOMEDIN C; SYNTHETASE; THIORETINACO; THIORETINACO OZONIDE; THIORETINAMIDE; THYROXINE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; AEROBIC GLYCOLYSIS; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; APOPTOSIS; ARTERIOSCLEROSIS; BIOSYNTHESIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; DEGENERATIVE DISEASE; DIET THERAPY; EMBRYO CELL; ENZYME ACTIVITY; FATTY LIVER; GLYCOLYSIS; HOMOCYSTINURIA; HORMONE SYNTHESIS; INBORN ERROR OF METABOLISM; INSULIN RESISTANCE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TROPHOBLAST; TUMOR PROMOTION; VITAMIN METABOLISM;

CYSTATHIONINE BETA-SYNTHASE; DISEASE; HOMOCYSTEINE; HUMANS; OXIDATION-REDUCTION; TRETINOIN; VITAMIN B 12;

CAVIA;

EID: 84855382309     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. McCully KS. Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci 1993;23:477-493.
2. McCully KS. Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism. Ann Clin Lab Sci 1994;24:27-59.
3. McCully KS. Chemical pathology of homocysteine. III. Cellular function and aging. Ann Clin Lab Sci 1994;24:134-152.
4. McCully KS. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci 2009;39:219-232.
5. Blom H. Diseases and drugs associated with hyperhomocysteinemia. In: R Carmel, DW Jacobsen, Eds. Homocysteine in Health and Disease Cambridge University Press, Cambridge, 2001; pp 331-340.
6. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
7. Kanwar YS, Manaligod JR, Wong WK. Morphologic studies in a patient with homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Pediatr Res 1976;10:598-609.
8. McCully KS. Homocysteine thiolactone metabolism in malignant cells. Cancer Res 1976;36:3198-3202.
9. Jakubowski H, Goldman E. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured malignant cells. FEBS Letters 1993;317:237-240.
10. McCully KS. Homocysteine thiolactone as a tumor promoter. U.S. Pat. No. 4,255,443. March 10, 1981.
11. McCully KS, Clopath P. Homocysteine compounds which influence the growth of a malignant neoplasm. Chemotherapy 1977;23:44-49.
12. McCully KS. Homocysteine thiolactone salts and use thereof as antineoplastic agents. U.S. Patent No. 4,383,994. May 17, 1983.
13. McCully KS, Vezeridis MP. Antineoplastic activity of a rhodium trichloride complex of oxalyl homocysteine thiolactone. Cancer Invest 1987;5:25-30.
14. McCully KS, Vezeridis MP. Antineoplastic activity of N-maleamide homocysteine thiolactone amide encapsulated within liposomes. Proc Soc Exp Biol Med 1985;180:57-61.
15. McCully KS, Vezeridis MP. Chemopreventive and antineoplastic activity of N-homocysteine thiolactonyl retinamide. Carcinogenesis 1987;8:1559-1562
16. McCully KS, Vezeridis MP. Chemopreventive effect of N-homocysteine thiolactonyl retinamido cobalamin on carcinogenesis by ethyl carbamate in mice. Proc Soc Exp Biol Med 1989;191:346-351.
17. Kazimir M, Wilson FR. Prevention of homocysteine thiolactone induced atherosclerosis in rats. Res Commun Molec Pathol Pharmacol 2002;5,6:179-198.
18. McCully KS. Thioretinaco ozonide and enhanced biological activity of thioretinaco ozonide in combination with interferon. U.S. Pat. No. 5,565,558. October 15, 1996.
19. McCully KS. Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier. U.S. Pat. No. 6,696,082. February 24, 2004.
20. McCully KS. Homocysteine metabolism in scurvy, growth and arteriosclerosis. Nature 1971;231:391-392.
21. Clopath P, Smith VC, McCully KS. Growth promotion by homocysteic acid. Science 1976;192:372-374.
22. McCully KS. Growth disorders and homocysteine metabolism. Ann Clin Lab Sci 1975;5:147-152.
23. McCully KS. Macromolecular basis for homocysteine-induced changes in proteoglycan structure in growth and arteriosclerosis. Am J Pathol 1972;66:83-95.
24. Hanck A. Ascorbic acid and cancer. In: Frank L. Myeskens Jr and Kedar N. Prasad, Eds, Vitamins and Cancer Humana Press, Clifton, New Jersey, 1986; pp 365-397.
25. Warburg O. The oxygen-transferring ferment of respiration. Nobel Lecture, December 10, 1931.
26. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
27. Schon R, Menke KH, Negelein E. The influence of heavy metal ions on the Ehrlich ascites tumor cells of mice and the effect of cysteine. Z Physiol Chem 1961;323:155-163.
28. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 1974;9:285-315.
29. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978;75:4538-4542.
30. Ingenbleek Y, Hardillier E, Jung L. Subclinical malnutrition is a determinant of hyperhomocysteinemia. Nutrition 2002;18:40-46.
31. Ingenbleek Y, McCully KS. Vegetarianism produces subclinical malnutrition, hyperhomocysteinemia and atherogenesis. Nutrition (2011), doi:10.1016/j.nut.2011.04.009
32. Ingenbleek Y, De Visscher M, De Nayer P. Measurement of prealbumin as index of protein-calorie malnutrition. Lancet 1972;2(7768):106-109.
33. Ingenbleek Y. Hyperhomocysteinemia is a biomarker for sulfur- deficiency in human morbidities. Open Clin Chem J 2009;2:49-60.
34. Carballal S, Madzelan P, Zinola CF, Grana M, Radi R, Banerjee R, Alvarez B. Dioxygen reactivity and heme redox potential of truncated human cystathionine β-synthase. Biochemistry 2008;47:3194-3202.
35. Smith TJ, Drummond GS. Retinoic acid can enhance the stimulation by thyroid hormone of heme oxygenase activity in the liver of thyroidectomized rats. Biochim Biophys Acta 1991;1075:119-122.
36. Samuel W, Kutty RK, Nagineni S, Vijaysarathy C, Chandraratna RAS, Wiggert B. N-(4-hydroxyphenyl) retinamide induces apoptosis in human retinal pigment epithelial cells: retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153. J Cell Physiol 2006;209:854-865.
37. Hail NJr, Kim HJ, Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006;11:1677-1694.
38. Miles EW, Kraus JP. Cystathionine β-synthase: structure, function, regulation, and location of homocystinuria-causing mutations. J Biol Chem 2004;279:29871-29874.
39. Kim J, Hong SJ, Park JH, Park SY, Kim SW, Cho EY, Do IG, Joh JW, Kim DS. Expression of cystathionine β-synthase is downregulated in hepatocellular carcinoma and associated with poor prognosis. Oncology Reports 2009;21:1449-1454.
40. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073-1077.
41. Huang ME, Ye YI, Chen SR. Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-572.
42. Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boivin P, Daniel MT, Berger R, Castaigne S, Degos L. Retinoic acid therapy for promyelocytic leukaemia. Lancet 1989;334(8665):746-747.
43. Ulukaya E, Wood EJ. Fenretinide and its relation to cancer. Cancer Treat Rev 1999;25:229-235.
44. Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 2004;61:1475-1484.
45. Moise AR, Noy N, Palczewski K, Blaner WS. Delivery of retinoid- based therapies to target tissues. Biochemistry 2007;46:4449-4458.
46. Holven KB, Natarajan V, Gundersen TE, Moskaug JO, Norum KR, Blomhoff R. Secretion of N-(4-hydroxyphenyl) retinamide-retinol binding protein from liver parenchymal cells: evidence for reduced affinity of the complex for transthyretin. Int J Cancer 1997;71:654-659.
47. Beard J. The Enzymatic Treatment of Cancer and its Scientific Basis, Chatto & Windus, London, 1911, republished by New Spring Press, New York, 2010 with a foreword by Nicholas Gonzalez.
48. Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropin- beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 1995;76:1467-1475.
49. Novak JF, Trynka F. Proenzyme therapy of cancer. Anticancer Res 2005;25:1157-1178.
50. Gonzalez N, Isaacs L. The Trophoblast and the Origins of Cancer, New Spring Press, New York, 2009.
51. Perla-Kajan J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 2007;32:561-572.
52. Liebow C, Rothman SS. Enteropancreatic circulation of digestive enzymes. Science 1975;189:472-474.
53. Rothman SS, Liebow C, Isenman L. Conservation of digestive enzymes. Physiol Rev 2002;82:1-18.
54. Gaull G, Sturman JA, Raiha NCR. Development of mammalian sulfur metabolism: absence of cystathionase in fetal tissues. Pediat Res 1972;6:538-547.
55. Schneider WC, Potter VR. Biocatalysts in cancer tissue. III. Succinic dehydrogenase and cytochrome oxidase. Cancer Research 1943;3:353-357.
56. Krebs ETJr. The nitrilosides in plants and animals. In: The Nitrilosides in the Prevention and Control of Cancer, McNaughton Foundation, Los Angeles, 1966; pp 1-21.
57. Tylleskar T, Banea M, Bikangi N, Cooke RD, Poulter NH, Rosling H. Cassava cyanogens and konzo, an upper motoneuron disease found in Africa. Lancet 1992;339:208-211.
58. Tor-Agbidye J, Palmer VS, Lasarev MR, Craig AM, Blythe LL, Sabri MI, Spencer PS. Bioactivation of cyanide to cyanate in sulfur amino acid deficiency: relevance to neurological disease in humans subsisting on cassava. Toxicol Sci 1999;50:228-235.
59. Sen U, Basu P, Abe OA, Giwimani S, Tyagi N, Metreveli N, Shah KS, Passmore JC, Tyagi SC. Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol 2009;297:F410-F419.
60. Olson KR, Whitfield NL. Hydrogen sulfide and oxygen sensing in the cardiovascular system. Antioxid Redox Signal 2010;12:1219-1234.
61. Chang L, Geng B, Yu F, Zhao J, Jiang H, Tang C. Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids 2008;34:573-585.
62. Wilson K, Mudra M, Furne J. Differentiation of the roles of sulfide oxidase and rhodanese in the detoxification of sulfide by the colonic mucosa. Dig Dis Sci 2008;53:277-283.
63. Ravnskov U, McCully KS. Vulnerable plaque formation from obstruction of vasa vasorum by homocysteinylated and oxidized lipoprotein aggregates complexed with microbial remnants and LDL autoantibodies. Ann Clin Lab Sci 2009;39:3-16.
64. Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovas Dis 1994;4:70-77.
65. Fife B. Stop Alzheimer's Now, Picadilly Books, Colorado Springs CO, 2011; pp 115-138.
66. Wentworth PJr, Nieva J, Takeuchi C, Galve R, Wentworth AD, Dilley RB, DeLaria GA, Saven A, Babior BM, Janda KD, Eschenmoser A, Lerner RA. Evidence for ozone formation in human atherosclerotic arteries. Science 2003;302:1053-1056.
67. Taylor CB, Peng SK, Werthessen NT, Tham P, Lee KT. Spontaneously occurring angiotoxic derivatives of cholesterol. Am J Clin Nutr 1979;32:40-57.
68. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005;112:651-657.
69. Huang H, Mai W, Liu D, Tao J, Dong Y. The oxidation ratio of LDL: a predictor for coronary artery disease. Dis Markers 2008;24:341-349.
70. Gaull GE, Schaffner F. Electron microscopic changes in hepatocytes of patients with homocystinuria. Pediat Res 1971;5:23-32.
71. Holmgren G, Falkmer S, Hambraeus L. Plasma insulin content and glucose tolerance in homocystinuria. Upsala J Med Sci 1973;78:215-216.
72. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L. The Natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37:1-31.
73. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D'Agostino RB, Wilson PWF. Fasting plasma homocysteine levels in the insulin resistance syndrome. Diabetes Care 2001;24:1403-1410.
74. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L, Kern PA. Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000;49:736-741.
75. Lustig RH. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc 2010;110:1307-1321.
76. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of the metabolic syndrome. Nature Rev Gastroent Hepatol 2010;7:251-264.
77. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-362.
78. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New Eng J Med 2006;354:2552-2563.
79. Johansson H, Gandine S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonnani B, Gulisano M, Magni P, Formelli F, Decense A. Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 2008;68:9512-9518.
80. Ingenbleek Y, Van Den Schrieck HG, De Nayer P, De Visscher M. The role of retinol-binding protein in protein-calorie malnutrition. Metabolism 1975;24:633-641.
81. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-1523.
82. Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007;18:184-195.
83. Chawla RK, Lewis FW, Kutner MH, Rudman D. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology 1984;87:770-776.
84. Lu SC, Alvarez L, Huang ZZ, Chen L, An W, Corrales FJ. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci USA 2001;98:5560-5565.
85. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver and the metabolic syndrome. Curr Opin Lipidol 2005;16:421-427.
86. Park SE, Kim DH, Lee JH, Park JS, Kand ES, Ahn CW, Lee HC, Cha BS. Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis 2009;204:23-25.
87. Bobbert T, Raila J, Schwarz F, Mai K, Henze A, Pfeiffer AFH, Schweigert FJ, Spranger J. Relation between retinol, retinolbinding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis 2010;213:549-551.
88. Gey KF, Ducimetiere P, Evans A, Amouyel P, Arveiler D, Ferrieres J, Luc G, Bingham A, Yarnell J, Cambien F. Low plasma retinol predicts coronary events in healthy middle-aged men: the PRIME Study. Atherosclerosis 2010;208:270-274.
89. Berry DC, Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferationactivated receptor β/γ and retinoic acid receptor. Molec Cell Biol 2009;29:3286-3296.
90. Manolescu DC, Sima A, Bhat PV. All-trans retinoic acid lowers serum retinol-binding protein 4 concentrations and increases insulin sensitivity in diabetic mice. J Nutr 2010;140:311-316.
91. Ziouzenkova O, Orasanu G, Sharlach M, Akiyama TE, Berger JP, Viereck J, Hamilton JA, Tang G, Dolnikowski GG, Vogel S, Duester G, Plutzky J. Retinaldehyde represses adipogenesis and diet-induced obesity. Nature Med 2007;13:695-702,
92. Yeste D, Vendrell J, Tomasini R, Gallart LL, Clemente M, Simon I, Albisu M, Gussinye M, Audi L, Carroscosa A. Retinol-binding protein 4 levels in obese children and adolescents with glucose intolerance. Horm Res Paediatr 2010;73:335-340.
93. Davila JA, Morgan RO, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533-539.
94. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma. Two growing epidemics with a potential link. Cancer 2009;115:5651-5661.
95. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-1766.
96. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-859.
97. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011;128:2436-2443.
98. Wang DD, Zhao YM, Wang L, Ren G, Wang F, Xia ZG, Wang XL, Zhang T, Pan Q, Dai Z, Chen JP, Dai HY, Zhang W, He HW, Zhou JM, Tang GY, Zhou J, Fan J, Tang ZY. Preoperative serum retinol-binding protein 4 is associated with the prognosis of patients with hepatocellular carcinoma after curative resection. J Cancer Res Clin Oncol 2011;137:651-658.
99. McCully KS. Compositions and method for utilization of thioretinamide in therapy of degenerative diseases of aging. US Patent Application 13/067,504. Filed June 6, 2011.